Lamberto Andreotti - Bristol-Myers Squibb

Lamberto Andreotti - Bristol-Myers Squibb
Total Compensation: $14.9 million

Details: Andreotti has the distinction of netting the top 10's highest year-to-year pay increase (excepting those who weren't CEOs in 2010), as last year's haul was almost $3.2 million more than the one prior. The majority of his raise was due to a $1.5 million growth in stock awards and a $1.1 million jump in non-equity incentive compensation.

In 2011, despite a drop in sales of some old standbys, BMS ($BMY) saw surprising growth with some of its newer products. Company flagship Plavix faltered a bit, but the drugmaker cashed in on leukemia drug Sprycel, diabetes pill Onglyza and antipsychotic Abilify. And Andreotti is starry-eyed about 2012's potential, despite getting rebuffed on a bid for Amylin ($AMLN). The CEO has plans to boost the company's multi-billion-dollar R&D department, and, living up to its "string of pearls" pedigree, BMS is likely to make some more noise in the M&A realm, too.

Lamberto Andreotti - Bristol-Myers Squibb
Read more on

Suggested Articles

Merck & Co. joined the pack in 2018 by hiring Jim Scholefield as its first chief digital officer. Now, less than two years in, he's moving on.

Teva is counting on Austedo for growth amid challenges elsewhere, and this week, the drug failed two trials in Tourette syndrome.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.